Simple exploration of 1172623-99-2

The synthetic route of 1172623-99-2 has been constantly updated, and we look forward to future research findings.

1172623-99-2, tert-Butyl ((2R,3S)-2-(2,5-difluorophenyl)-5-hydroxytetrahydro-2H-pyran-3-yl)carbamate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 1 Hg (11.53 g, 35.03 mmol)Was dissolved in dichloromethane (130 mL) and cooled to 0 C. Dess-Martin periodinane (29.72 g, 70.06 mmol) was added portionwise to the reaction solution and allowed to warm to room temperature for 4 hours The Down to 0 C,The saturated sodium bicarbonate solution (60mL) was added dropwise to the reaction solution, stirred for 20 minutes, filtered, the filtrate was allowed to stand and the aqueous phase was extracted with methyl tertiary butyl ether (60 mL chi 3) (30 mL chi 2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography (petroleum ether / ethyl acetate (nu / nu) = 10: 1 – 4: 1) to give white crystalline powder intermediate 1 (10.85 g, yield 94.7%), 1172623-99-2

The synthetic route of 1172623-99-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SICHUAN HAISCO PHARMACEUTICAL CO., LTD; FAN, JIANG; FENG, JIAN-CHUAN; PENG, FEI; CHEN, QING-PING; (89 pag.)TW2017/8224; (2017); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Downstream synthetic route of 1228779-96-1

1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various.

1228779-96-1, 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Add Intermediate V4 (46.7g, 63mmol, 1.0eq), Intermediate VM4 (21.7g, 69mmol, 1.1eq) and 800mL dichloromethane to a 1000mL reaction flask, dissolve with stirring, and then add EDCI (14.6g, 76mmol, 1.2 eq) and 4.7g DMAP, the temperature was raised to 30-35 reaction, TLC monitored the reaction.After the reaction was completed, 1L of 10% acetic acid aqueous solution was added and stirred for 30min to separate the organic phase. The organic phase was washed with saturated aqueous sodium bicarbonate solution (300mL ¡Á 1), saturated aqueous sodium chloride solution (300mL ¡Á 1), and dried over anhydrous sodium sulfate. Filter with suction and concentrate the filtrate under reduced pressure to obtain a crude solid. The crude product was recrystallized with 300 mL of ethyl acetate and n-hexane (1: 1),56.8 g of solid product V5 was obtained. Yield: 88%., 1228779-96-1

1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Nantong Changyou Pharmaceutical Technology Co., Ltd.; Li Zebiao; Chen Dan; Wu Hongdang; Xu Xiaohong; Lin Yanfeng; (9 pag.)CN110878098; (2020); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Brief introduction of 53911-68-5

The synthetic route of 53911-68-5 has been constantly updated, and we look forward to future research findings.

53911-68-5, 4-(4-Chlorophenyl)dihydro-2H-pyran-2,6(3H)-dione is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,53911-68-5

General procedure: The N-hydroxy compounds were prepared by the following procedure. 4-substituted anhydride (1 mol) and hydroxylamine hydrochloride (1.14 mol) were suspended in isopropanol (150 mL). A solution of 46% sodium hydroxide solution (3 mol) was added to the mixture was and vigorously stirred for 4 h at 60-65C. The mixture was then acidified to pH 2 by 2 N HCl and extracted with dichloromethane. The dichloromethane layer was evaporated under vacuum the solid thus formed was filtered and recrystallized using methanol.

The synthetic route of 53911-68-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ponnusamy, Kannan; Davis Presley; Nagapillai, Prakash; Deivanayagam, Eswaramoorthy; Indian Journal of Heterocyclic Chemistry; vol. 28; 2; (2018); p. 275 – 278;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Analyzing the synthesis route of 1240390-36-6

1240390-36-6, As the paragraph descriping shows that 1240390-36-6 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1240390-36-6,tert-Butyl ((3R,4R)-4-aminotetrahydro-2H-pyran-3-yl)carbamate,as a common compound, the synthetic route is as follows.

Step 5 {(3R,4R)-4-[7-(Thiazolo[4,5-b]pyridine-2-ylcarbamoyl)-thieno[3,2-d]pyrimidin-2-ylamino]-tetrahydro-pyran-3-yl}-carbamic acid tert-butyl ester To a solution of 2-chloro-N-(thiazolo[4,5-b]pyridin-2-yl)thieno[3,2-d]pyrimidine-7-carboxamide (0.162 g, 0.466 mmol) and tert-butyl (3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (0.151 g, 0.699 mmol) in dioxane (4 mL) was added diisopropylethylamine (0.244 mL, 1.4 mmol). The reaction mixture was heated at 120 C. overnight. The reaction mixture was cooled and then diluted with dichloromethane, washed with aqueous sodium carbonate, then brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue obtained was then purified by chromatography (silica, 40 g, 0 to 15% MeOH in dichloromethane) to give {(3R,4R)-4-[7-(thiazolo[4,5-b]pyridine-2-ylcarbamoyl)-thieno[3,2-d]pyrimidin-2-ylamino]-tetrahydro-pyran-3-yl}-carbamic acid tert-butyl ester (0.118 g, 0.224 mmol, 48%) as a yellow solid. LCMS m/z [M+H]=528.

1240390-36-6, As the paragraph descriping shows that 1240390-36-6 is playing an increasingly important role.

Reference£º
Patent; Hoffmann-La Roche Inc.; Chen, Shaoqing; Hermann, Johannes Cornelius; Le, Nam T.; Lucas, Matthew C.; Padilla, Fernando; US2013/178460; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Some tips on 1228779-96-1

The synthetic route of 1228779-96-1 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.

Into a 8-mL round-bottom flask, was placed 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex -l-en-l-yl]methyl]piperazin-l-yl)-2- [l2,l2-difluoro-l4-oxa-2,4,l0-triazatricyclo[7.5.0.0A[3,7]]tetradeca-l(9),2,5,7-tetraen-l0- yl]benzoic acid (20.00 mg, 0.030 mmol, 1.00 equiv), 3-nitro-4-[[(oxan-4-yl)methyl]amino] benzene- l-sulfonamide (11.43 mg, 0.036 mmol, 1.2 equiv), DCM (3 mL), DMAP (14.76 mg, 0.121 mmol, 4 equiv), EDCI (11.58 mg, 0.060 mmol, 2 equiv). The resulting solution was stirred for 12 h at room temperature. The crude product was purified by Prep-HPLC with the following conditions (Waters-2767): Column, X-bridge RP18, 5um, l9* l00mm; mobile phase, 0.03% ammonia in water (0.03% NH4HCO3 & NH4OH) and CH3CN (32% CH3CN up to 52% in 6 min); Detector, UV 254 nm. This resulted in 11.5 mg (39.68%) of 4-(4-[[2-(4- chlorophenyl)-4,4-dimethylcyclohex- l-en- l-yl]methyl]piperazin- l-yl)-2-[l2, 12- difluoro- l4-oxa-2,4,l0-triazatricyclo[7.5.0.0A[3,7]]tetradeca-l(9),2,5,7-tetraen-l0-yl]-N-(3-nitro-4- [[(oxan-4-yl)methyl]amino]benzenesulfonyl)benzamide as a white solid. LC-MS-0: (ES, m/z) M+l=96l.47. 1H-NMR-0(300MHz, d-DMSO, ppm): 511.01 (s, 1H), 8.34-8.33 (d, / =3.0 Hz, 1H), 7.47-7.45 (m, 2H), 7.38-7.35 (m, 2H), 6.82-6.80 (m, 3H), 6.02 (s, 1H), 3.86- 3.51 (m, 7H), 3.39-3.17 (m, 5H), 2.77-2.73 (m, 2H), 2.24-2.20 (m, 6H), 2.00 (s, 2H), 1.42 (m, 2H), 1.30 (s, 1H), 0.95 (s, 6H)., 1228779-96-1

The synthetic route of 1228779-96-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NEWAVE PHARMACEUTICAL INC.; CHEN, Yi; (475 pag.)WO2020/41406; (2020); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Brief introduction of 101691-94-5

As the paragraph descriping shows that 101691-94-5 is playing an increasingly important role.

101691-94-5, 4-(Iodomethyl)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,101691-94-5

A solution of 4-(iodomethyl)tetrahydro-2H-pyran ([101691-94-5], 565 mg, 3 mmol) in LiC1 solution (0.5 M in THF, 5 mL, 3 mmol) was pumped using the R2 + R4 through a column containing activated Zn (12 g) at 0.5 mL/min at 60 C. Titration with 12/LiC1 showed a concentration of organozinc reagent of 0.28 M. The solution was used in the next step without further purification.

As the paragraph descriping shows that 101691-94-5 is playing an increasingly important role.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; VOS, Ann, Marleen; OEHLRICH, Daniel; GIJSEN, Henricus, Jacobus, Maria; WATTS, Karl, Shawn; BHAT, Sathesh, Pangala; BUIJNSTERS, Peter, Jacobus, Johannes, Antonius; VAN BRANDT, Sven, Franciscus, Anna; ALCAZAR-VACA, Manuel, Jesus; (57 pag.)WO2018/162444; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Downstream synthetic route of 65412-03-5

As the paragraph descriping shows that 65412-03-5 is playing an increasingly important role.

65412-03-5,65412-03-5, 4-(2-Aminoethyl)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2,4,6-Trichlorophenyl 1-benzyl-5-(methylcarbamoyl)-6-oxo- 1,6-dihyd ropyrid ine-3- carboxylate (61 mg, 0.13 1 mmol), 2-(tetrahydro-2H-pyran-4-yl)ethanamine (33.8 mg, 0.262 mmol), N,N-dimethylpyridin-4-amine (4 mg, 0.033 mmol),triethylamine (0.05 mL, 0.359 mmol) and THF (1mL) were stirred at 45 C for 4 h. A white precipitate formed which was filtered to give 31 mg of a white solid. This was purified by chromatography on Si02 (Biotage SNAP 10 g cartridge, eluting with O-100% ethyl acetate/(25% ethanol in ethyl acetate)). The appropriate fractions were collected and concentrated to give 1-benzyl-N3-methyl-2-oxo-N5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)- 1,2- dihydropyridine-3,5-dicarboxamide (9 mg, 0.020 mmol, 15.56 % yield) as a white solidLCMS (2mm Formic): Rt=0.89 mi [MH] = 398.

As the paragraph descriping shows that 65412-03-5 is playing an increasingly important role.

Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; ATKINSON, Stephen John; DEMONT, Emmanuel Hubert; HARRISON, Lee Andrew; HAYHOW, Thomas George Christopher; HOUSE, David; LINDON, Matthew J; PRESTON, Alexander G; SEAL, Jonathan Thomas; WALL, Ian David; WATSON, Robert J; WOOLVEN, James Michael; (141 pag.)WO2017/50714; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Downstream synthetic route of 25850-22-0

As the paragraph descriping shows that 25850-22-0 is playing an increasingly important role.

25850-22-0, 2,2-Dimethyltetrahydro-2H-pyran-4-amine is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(4) (2E)-3-{1-[bis(4-fluorophenyl)methyl]-3-cyano-4,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(2,2-dimethyltetrahydro-2H-pyran-4-yl)prop-2-enamide To a solution of (2E)-3-{1-[bis(4-fluorophenyl)methyl]-3-cyano-4,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-yl}prop-2-enoic acid (300 mg, 0.677 mmol) in THF (3 ml) were added DMF (0.03ml) and oxalylchloride (0.071 ml, 0.813 mmol), the mixture was stirred at room temperature for 1 hour and the solvent was distilled off under reduced pressure. The residue was added under ice-cooling to a solution of 2,2-dimethyltetrahydro-2H-pyran-4-ylamine (175 mg, 1.35 mmol), triethylamine (0.313 ml, 2.25 mmol) and THF (2 ml), and the mixture was stirred under ice-cooling for 2 hours. The reaction solution was poured into water and extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to give the objective product as a solid material. Yield (amount) 177 mg, yield (rate) 47.1% 1H-NMR (CDCl3) delta: 1.18-1.40 (8H, m), 1.80-1.90 (2H, m), 2.56 (3H, s), 2.75 (3H, s), 3.69-3.77 (2H, m), 4.16-4.21 (1H, m), 5.49 (1H, d, J = 7.6 Hz), 6.78 (1H, d, J = 15.8 Hz), 6.92-7.26 (9H, m), 7.44 (1H, d, J = 15.8 Hz), 7.94 (1H, s). IR (KBr) cm-1; 3289, 2216, 1661, 1607, 1510, 1333, 1231, 1159, 733., 25850-22-0

As the paragraph descriping shows that 25850-22-0 is playing an increasingly important role.

Reference£º
Patent; Takeda Pharmaceutical Company Limited; EP1535922; (2005); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

New learning discoveries about 137052-08-5

137052-08-5 1-(Tetrahydro-2H-pyran-4-yl)ethanone 9877365, aTetrahydropyrans compound, is more and more widely used in various.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137052-08-5,1-(Tetrahydro-2H-pyran-4-yl)ethanone,as a common compound, the synthetic route is as follows.

Add in a 50mL single-mouth bottle2-(5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6-triamine (0.11 g, 0.30 Mm),1-(tetrahydro-2H-pyran-4-yl)ethanone (0.050 g, 0.39 mmol) and methanol (10 mL),Acetic acid (0.17 mL, 3.0 mmol) was added at 0 C.After stirring at room temperature for 1 hour and then cooled to 0 C, sodium cyanoborohydride (0.094 g, 1.5 mmol) was added.It was then stirred at room temperature overnight.Evaporation of the solvent, EtOAc (EtOAc)The organic phase was washed with water (30 mL) and brine (30 mL)The residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) = 80/1, 0.5% triethylamine)A pale yellow solid (0.036 g, 25.0%)., 137052-08-5

137052-08-5 1-(Tetrahydro-2H-pyran-4-yl)ethanone 9877365, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Guangdong Dongyangguang Pharmaceutical Co., Ltd.; Wang Xiaojun; Zuo Yinglin; Yu Chuan; Yang Chuanwen; Wang Jiancheng; Li Jing; Cao Shengtian; Wu Fangyuan; Zhang Yingjun; S ¡¤geerdeman; (79 pag.)CN108690016; (2018); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Brief introduction of 14774-37-9

As the paragraph descriping shows that 14774-37-9 is playing an increasingly important role.

14774-37-9, Tetrahydropyran-4-methanol is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate 077 N-(2,4-Dimethoxybenzyl)-5-nitro-2-(tetrahydro-2H-pyran-4- ylmethoxy)benzenesulfonamide 2-Chloro-N-(2,4-dimethoxybenzyl)-5-nitrobenzenesulfonamide (2.00 g, 5.17 mmol) was dissolved in dimethylformamide (10 mL), treated with tetrahydro-2H-pyran-4-ylmethanol (901 mg, 7.76 mmol) and sodium hydride (1.58 g, 36.2 mmoL) and was stirred for 2 hours at room temperature. It was quenched under ice cooling with water/ethyl acetate. The phases were separated, the aqueous phase was three times reextracted with ethyl acetate and all organic phases were combined, dried and concentrated in vacuo. It was tehn stirres with ethyl acetate/methyl tert.-butyl ether (1/2) until a white solid precipitated. Filtration led to N-(2,4-dimethoxybenzyl)-5-nitro-2-(tetrahydro-2H-pyran-4- ylmethoxy)benzenesulfonamide (2.20 g, 4.75 mmol, 91% yield, 95% purity) LC-MS (Method A): Rt = 1.16 min MS (ESIneg): m/z = 465 (M-H)+ 1H-NMR (400MHz, DMSO-d6) [ppm]: 1.23 – 1.36 (m, 2H), 1.70 – 1.77 (m, 2H), 2.09 – 2.23 (m, 1H), 3.29 – 3.39 (m, 2H), 3.59 (s, 3H), 3.65 (s, 3H), 3.89 (dd, 2H), 3.99 (d, 2H), 4.08 (s, 2H), 6.21 (d, 1H), 6.30 (dd, 1H), 7.01 (d, 1H), 7.25 (d, 1H), 7.42 (s, 1H), 8.23 (d, 1H), 8.31 (dd, 1H)., 14774-37-9

As the paragraph descriping shows that 14774-37-9 is playing an increasingly important role.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; WERNER, Stefan; MESCH, Stefanie; BRAeUER, Nico; POOK, Elisabeth; DAHLLOeF, Henrik; NUBBEMEYER, Reinhard; OSMERS, Maren; KALTHOF, Bernd; (386 pag.)WO2016/198374; (2016); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics